Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company